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ABSTRACT 
Background: Although the possibility of bleeding during anticoagulant treatment may 
limit patients from taking part in physical activity, the association between physical 
activity and anticoagulation-related bleeding is uncertain. 
Objectives: To determine whether physical activity is associated with bleeding in 
elderly patients taking anticoagulants. 
Patients/Methods: In a prospective multicenter cohort study of 988 patients aged 
≥65 years receiving anticoagulants for venous thromboembolism, we assessed 
patients’ self-reported physical activity level. The primary outcome was the time to a 
first major bleeding, defined as fatal bleeding, symptomatic bleeding in a critical site, 
or bleeding causing a fall in hemoglobin or leading to transfusions. The secondary 
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outcome was the time to a first clinically-relevant non-major bleeding. We examined 
the association between physical activity level and time to a first bleeding using 
competing risk regression, accounting for death as a competing event. We adjusted 
for known bleeding risk factors and anticoagulation as a time-varying covariate. 
Results: During a mean follow-up of 22 months, patients with a low, moderate, and 
high physical activity level had an incidence of major bleeding of 11.6, 6.3, and 3.1 
events per 100 patient-years, and an incidence of clinically relevant non-major 
bleeding of 14.0, 10.3, and 7.7 events per 100 patient-years, respectively. A high 
physical activity level was significantly associated with a lower risk of major bleeding 
(adjusted sub-hazard ratio 0.40, 95%-CI 0.22-0.72). There was no association 
between physical activity and non-major bleeding. 
Conclusions: A high level of physical activity is associated with a decreased risk of 
major bleeding in elderly patients receiving anticoagulant therapy. 
 
Trial Registration: http://clinicaltrials.gov. Identifier: NCT00973596. 
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INTRODUCTION 
The multiple benefits of regular physical activity on morbidity and mortality are well 
known (1-4). Elderly persons who are physically active are less likely to have falls and fall-
related severe injuries, such as fractures (5-7) but the data on the effect of physical activity 
on the risk of bleeding are conflicting. While studies showed that physical activity is 
associated with a lower risk of severe gastrointestinal hemorrhage and hemorrhagic stroke 
(8, 9), other studies demonstrated that vigorous physical activity is related to an increased 
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risk of subarachnoid hemorrhage in adults and bleeding events in children with hemophilia 
(10, 11). 
Limited evidence suggests that the fear of anticoagulation-related bleeding may limit 
patients from taking part in vigorous physical activity (12). Moreover, it has been shown that 
a below-average level of physical activity may be associated with excessive anticoagulation 
(13). A potential explanation is that physical activity decreases the anticoagulant effect by 
decreasing the free warfarin concentration and thus may contribute to a better stability of 
the response to warfarin (14, 15). However, to our knowledge, the relationship between 
physical activity and the risk of bleeding in patients receiving anticoagulant therapy has 
never been specifically examined. Therefore, we assessed the association between physical 
activity and bleeding in a prospective, multicenter cohort of elderly patients receiving 
anticoagulants for venous thromboembolism (VTE). Because elderly persons who are 
physically active are less likely to fall (5-7), we hypothesized that a higher level of physical 
activity will be associated with a lower risk of bleeding. 
 
METHODS 
Cohort sample 
The study was conducted between September 2009 and April 2013 as part of the 
Swiss Cohort of Elderly Patients with Venous Thromboembolism (SWITCO65+), a prospective 
multicenter cohort study to assess long-term medical outcomes and quality of life in elderly 
patients with acute VTE from all five university and four high-volume non-university 
hospitals in Switzerland (16). 
Consecutive patients aged ≥65 years with acute VTE were identified in the inpatient 
and outpatient services of all participating study sites. We defined symptomatic deep vein 
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thrombosis as an acute onset of leg pain or swelling in conjunction with incomplete 
compressibility of a venous segment on ultrasonography or an intraluminal filling defect on 
contrast venography (17). Because iliac veins and the inferior vena cava may be technically 
difficult to compress, additional diagnostic criteria for iliac and caval deep vein thrombosis 
also included abnormal duplex flow patterns compatible with thrombosis or an intraluminal 
filling defect on spiral computed tomography or magnetic resonance imaging venography 
(18-20). Given that compression ultrasonography has a lower likelihood ratio for distal deep 
vein thrombosis (21), patients with isolated distal deep vein thrombosis were eligible only if 
the incompressible distal vein transverse diameter was at least 5 mm (22). 
Symptomatic pulmonary embolism was defined as a positive spiral computed 
tomography or pulmonary angiography, a high probability ventilation-perfusion scan, or 
proximal deep vein thrombosis documented by compression ultrasonography or contrast 
venography in patients with acute chest pain, new or worsening dyspnea, hemoptysis, or 
syncope (23, 24). 
Exclusion criteria were inability to provide informed consent (i.e., severe dementia), 
conditions incompatible with follow-up (i.e., terminal illness or place of living too far away 
from the study center), insufficient German or French speaking ability, thrombosis at a 
different site than lower limb, catheter-related thrombosis, or previous enrollment in the 
cohort. 
Eligible patients were approached for informed consent to participate in the study. 
The study was approved by the ethics committees at each study site and written informed 
consent was obtained from all participants. A detailed description of the study methods has 
previously been published (16). 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Baseline data collection 
For all enrolled patients, trained study nurses prospectively collected baseline 
demographic information (age, gender), comorbid conditions (history of major bleeding, 
recent major surgery, cerebrovascular disease, cardiac disease, diabetes mellitus, 
hypertension, active cancer, and chronic liver and renal disease), risk of falls, laboratory 
findings (hemoglobin, platelets), polypharmacy (>4 drugs), concomitant antiplatelet therapy, 
pre-existing vitamin K antagonist therapy, and VTE-related treatment (low-molecular-weight 
heparin, unfractionated heparin, fondaparinux, vitamin K antagonists) using patient 
interviews and hospital chart review. Collected data were recorded on standardized forms. 
 
Assessment of physical activity 
To assess patients’ physical activity level at baseline, we asked patients a previously 
established standard question (“Which of the following affirmation best matches the type 
and amount of physical activity you do in your life?”), with four possible answers (25). 
Patients who replied “I am mostly sitting or lying and I do not move a lot” or “I often walk 
but I avoid to climb stairs or to carry light weight (<5 kg)” were considered to have a low 
physical activity level. Patients who replied “I often walk and climb stairs or carry light 
weight (<5 kg)” and “I engage in vigorous physical activity or carry heavy weight (>5 kg)” 
were considered to have a moderate and high physical activity level, respectively. 
 
Study outcomes 
Our primary outcome was the time to a first major bleeding event during follow-up. 
Major bleeding was defined as either fatal bleeding (death that followed an intracranial 
hemorrhage or a bleeding episode leading to hemodynamic deterioration) (26), 
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symptomatic bleeding in a critical area or organ (intracranial, intraspinal, intraocular, 
retroperitoneal, intraarticular, pericardial, or intramuscular with compartment syndrome), 
bleeding causing a fall in hemoglobin level of ≥ 20 g/l or leading to transfusion of ≥2 units of 
whole blood or red cells (27). The secondary outcome was the time to the first clinically 
relevant non-major bleeding, defined as a bleeding episode not meeting the definition of 
major bleeding but requiring a physician consultation or a visit at the emergency 
department. We also assessed whether bleeding occurred after a fall. 
Follow-up included one telephone interview and two surveillance face-to-face 
evaluations during the first year of study participation and then semi-annual contacts, 
alternating between face-to-face evaluations (clinic visits or home visits in house-bound 
patients) and telephone calls as well as periodic reviews of the patient’s hospital chart. 
During each visit/contact, study nurses interviewed patients to obtain information about the 
date, type, and circumstances (i.e., following a fall) of bleeding episodes, and assessed 
whether the patient had died. If a clinical event had occurred, this information was 
complemented by reviewing medical charts and interviewing patients’ primary care 
physicians and/or family members. We also collected international normalized ratio (INR) 
values throughout follow-up. A committee of three blinded clinical experts adjudicated all 
outcomes and classified the cause of all deaths as definitely due to major bleeding or due to 
another cause. Final classifications were made on the basis of the full consensus of this 
committee. 
 
Statistical analysis 
We calculated overall incidence rates with corresponding 95% confidence intervals 
(CI) for a first major, clinically relevant non-major, and fall-related bleeding by physical 
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activity level and compared cumulative incidences using Kaplan-Meier survival analyses and 
the logrank test. In patients who received vitamin K antagonists within 14 days from 
diagnosis, we compared the percentage of time spent in a given INR range (<2.0, 2.0-3.0, 
>3.0) (28) across physical activity groups by an analysis of variance, excluding the first seven 
days of treatment. 
 
We examined the associations between physical activity and the time to a first major, 
clinically relevant non-major bleeding, and fall-related bleeding using competing risk 
regression models according to Fine and Gray, accounting for death as a competing event 
(29). We accounted for non-hemorrhagic death as a competing event when analyzing major 
bleeding and overall death when analyzing clinically-relevant non-major bleeding. The 
strength of the association between the physical activity and bleeding in the Fine and Gray 
model is reflected by the sub-hazard ratio (SHR), which is the ratio of hazards associated 
with the cumulative incidence function in the presence of a competing risk. We adjusted for 
risk factors that have been previously shown to be associated with major bleedings, 
including age, female gender, overt pulmonary embolism, history of major bleeding, recent 
major surgery, cerebrovascular disease, cardiac disease, diabetes mellitus, arterial 
hypertension, active cancer, chronic liver disease, chronic renal disease, risk of falls, 
polypharmacy, anemia, low platelets, concomitant antiplatelet therapy, and periods of 
anticoagulation as a time-varying covariate (30-47). In the primary analysis we assumed 
missing values for categorical variables to be normal/absent, but tested the impact on study 
results by assuming missing values to be abnormal/present in a sensitivity analysis. We 
considered a P value <0.05 to be statistically significant. All analyses were done using Stata 
12 (Stata Corporation, College Station, Texas). 
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RESULTS 
Study sample 
Of 1863 patients aged ≥65 years with venous thromboembolism, we excluded 462 
patients who had at least one exclusion criterion and 398 who did not consent to participate. 
After the additional exclusion of 12 patients who withdrew informed consent and three 
patients in whom information on physical activity was not available, a study sample of 988 
subjects was included in the analysis (Figure 1). Excluded patients were statistically 
significantly older (median 78 vs. 75 years, P <0.001) and more often female (59% vs. 47%, P 
<0.001) than analyzed patients. 
Overall, 367 (37%), 310 (31%), and 311 (32%) patients had a low, moderate, and high 
level of physical activity, respectively. Patients with a high level of physical activity were 
younger, more likely to be men, and less likely to have comorbid diseases, a high risk of falls, 
polypharmacy, and concomitant treatment with platelet inhibitors than patients with low or 
moderate level of physical activity (Table 1). 
 
Comparison of bleeding rates 
After a mean ± standard deviation follow-up period of 22 ± 11 months, 184 of 988 
patients (19%) died and 118 (12%) experienced a first major bleeding, resulting in an 
incidence rate of 6.9 (95% CI, 5.7-8.2) major bleeds per 100 patient-years. Seventeen (14%) 
major bleeds were intracranial and 9 (8%) were fatal. Overall, 174 patients (18%) had a first 
clinically relevant non-major bleeding and 60 (6%) had a fall-related major or clinically 
relevant non-major bleeding, resulting in an incidence rate of 10.6 (95% CI, 9.1-12.3) and 3.4 
(95% CI, 2.6-4.3) bleeds per 100 patient-years, respectively. Patients with unprovoked VTE 
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had an average anticoagulation duration of 16 patient-months compared to 9 patient-
months for patients with provoked or cancer-related VTE. 
Overall incidence rates of major and clinically relevant non-major bleeding decreased 
with increasing physical activity level (Table 2). Compared to patients with a low level of 
physical activity, patients with a high level had a lower incidence rate of major (3.1 vs. 11.6 
bleeds per 100 patient-years) and clinically relevant non-major bleedings (7.7 vs. 14.0 bleeds 
per 100 patient-years). Patients with a high level of physical activity also had a lower rate of 
fall-related bleeding (2.1 bleeds per 100 patient-years) than patients with a low physical 
activity level (6.1 bleeds per 100 patient-years). The incidence rate of fall-related major 
bleeds decreased from 2.5 bleeds per 100 patient-years in patients with a low physical 
activity level to 0.3 events per 100 patient-years in patients with a high physical activity level 
(P=0.001). Similarly, the incidence rate of fall-related clinically relevant non-major bleeds 
decreased from 3.8 bleeds per 100 patient-years in patients with a low physical activity level 
to 1.7 events per 100 patient-years in patients with a high physical activity level (P=0.007). 
The 2-year cumulative incidence rates of major, clinically relevant non-major, and fall-
related bleeding are shown in Figure 2 A-C. 
The time spent in the therapeutic INR range (2.0-3.0) increased from 54% in patients 
with a low physical activity level to 63% in patients with a high physical activity level (Table 
3). Patients with a low physical activity level spent more time in the subtherapeutic INR 
range (<2.0). Although the time spent in the supratherapeutic INR range (>3.0) did not vary 
across physical activity levels, the majority of major bleedings (68%) related to excessive 
anticoagulation occurred in patients with a low physical activity level. 
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Association between the level of physical activity and bleeding 
After adjustment for multiple confounding factors, patients with a high physical 
activity level had a significantly lower risk (SHR 0.40, 95% CI 0.22-0.72) and patients with a 
moderate physical activity level had a non-significantly lower risk of major bleeding (SHR 
0.72, 95% CI 0.45-1.13) than patients with a low physical activity level (Table 4). The level of 
physical activity was not associated with the risk of clinically relevant non-major bleeding. 
However, we found a positive association between the risk of falls (adjusted SHR 1.75, 95% 
CI 1.24-2.48), polypharmacy (adjusted SHR1.63, 95% CI 1.12-2.37) and non-major bleeding. 
The results did not change when missing values were assumed to be abnormal in a 
sensitivity analysis. 
 
DISCUSSION 
Our results demonstrate that in elderly patients receiving anticoagulants for VTE, the 
incidence of major and clinically relevant non-major bleedings decreases with increasing 
levels of self-reported physical activity. After adjusting for potential confounders, including 
the competing risk for death, we found that patients with a high level of physical activity had 
a significantly lower risk of major bleeding than patients with a low level of physical activity 
and that the bleeding risk decreased with the intensity of physical activity. The level of 
physical activity was not associated with risk of clinically relevant non-major bleeding. 
There are several potential explanations for the observed association between physical 
activity and major bleeding. First, patients with a high level of physical activity had a lower 
incidence of fall-related bleedings in our study. This finding is consistent with prior evidence 
demonstrating that low levels of fitness and physical inactivity are associated with falls (6) 
and that exercise programs reduce the risk of falling in the elderly (48). Second, patients with 
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increasing level of physical activity spent more time in a therapeutic INR range, indicating 
that physical activity may have a stabilizing effect on the response to vitamin K antagonists. 
In a small case series, INR values remained stable during a constant level of physical activity, 
decreased with increased daily activity, and increased following a reduction in physical 
activity (15). The authors hypothesized that increased physical activity elevates the amount 
of warfarin linked to serum albumin, decreases the free warfarin concentration and 
subsequently, decreases the INR (15). A case-control study demonstrated that in comparison 
with patients whose level of physical activity was above average, patients with a below-
average level of physical activity had a 1.6-fold increased risk of excessive anticoagulation 
(13). Finally, a low level of physical activity may reflect patients’ comorbid burden, an 
independent predictor of serious bleeding (49). Moreover, despite extensive adjustment, we 
cannot exclude the possibility that the association between physical activity and major 
bleeding is due to incomplete adjustment or unmeasured confounders rather than a direct 
effect of physical activity itself. 
Patients taking anticoagulants may feel limited from taking part in vigorous physical 
activities by the fear of bleeding (12). Our results indicate that physical activity does not 
increase the risk of bleeding and may encourage patients to continue physical activity with 
all its positive effects on health and well-being. 
Although patients with a higher physical activity lever had a lower incidence of 
clinically relevant non-major bleeding, after adjustment for differences in baseline 
characteristics, we did not find an association between physical activity level and non-major 
bleeds. Only the risk of falls and polypharmacy were associated with non-major bleeding. 
We can only speculate why physical activity could have a protective effect on major bleeding 
but not on non-major bleeding. A potential explanation is that patients with a higher 
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physical activity level may experience fewer severe falls, hence avoiding major bleeds but 
only to a lesser extent, non-major bleeds. 
Our findings have clinical and research implications. Given their increased risk of 
excessive anticoagulation and major bleeding, frail and physically inactive patients could 
potentially benefit from more intensive surveillance and anticoagulation monitoring (13). 
Further studies are needed to explore the mechanisms by which physical activity decreases 
the risk of major bleeding (e.g., reduced falls risk, better anticoagulation quality) and 
whether exercise programs have the potential to reduce the risk of bleeding in elderly 
patients receiving anticoagulants. The level of physical activity should also be incorporated in 
future bleeding risk prediction models. 
Our study has several strengths. First, to our knowledge, our study is the first to 
examine the association between physical activity and bleeding in patients receiving 
anticoagulants. Second, because practically all patients with acute VTE receive 
anticoagulation for at least three months regardless of their bleeding risk, the potential for 
indication bias is low. Indication bias is a threat to the validity of anticoagulation-related 
bleeding studies because physicians may decide against treating patients who they perceive 
to be at high-risk of bleeding (50). Finally, because our sample included elderly, multimorbid 
patients who were at risk of dying from non-hemorrhagic causes before experiencing a 
bleeding event, we used competing risk regression to account for the competing risk of 
death (29). 
Our study has several potential limitations. First, the study sample may not reflect the 
full prognostic spectrum of patients with VTE because analyzed patients were younger and 
more likely to be men than excluded patients. Thus, we cannot rule out the possibility that 
the association between physical activity and bleeding would have been different in more 
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severely ill patients. Second, given that our cohort included patients with VTE only, our 
results may not be generalizable to other indications for anticoagulant treatment. Third, 
physical activity was only assessed at the beginning of the study and may have changed over 
time. Finally, we could only detect associations, not causality. Thus, we could not determine 
whether the level of physical activity has a direct causal effect on major bleeding or if it is 
simply a marker of comorbidity. 
In conclusion, in this prospective multicenter cohort of elderly patients receiving 
anticoagulant treatment, a high level of physical activity was associated with a lower risk of 
major bleeding. Future studies should examine the mechanisms by which physical activity 
decreases the risk of bleeding and whether implementation of training programs aimed to 
increase physical activity decrease the risk of bleeding in such patients. 
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FIGURE LEGENDS 
Figure 1 
Patients flow chart. 
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Figure 2 
Panel A. Kaplan-Meier estimates of a first major bleeding by physical activity level 
The 2-year cumulative incidence of a first major bleeding was 18.8%, 11.4%, and 6.2% for 
patients with a low, moderate, and high physical activity level, respectively (P<0.001 by the 
logrank test). 
 
Panel B. Kaplan-Meier estimates of a first clinically relevant non-major bleeding by 
physical activity level 
The 2-year cumulative incidence of a first clinically relevant non-major bleeding was 22.1%, 
18.1%, and 13.4% for patients with a low, moderate, and high physical activity level, 
respectively (P=0.01 by the logrank test). 
 
Panel C. Kaplan-Meier estimates of a first fall-related major or clinically relevant non-
major bleeding by physical activity level 
The 2-year cumulative incidence of a first fall-related bleeding was 9.9%, 3.9%, and 4.1% for 
patients with a low, moderate, and high physical activity level, respectively (P<0.001 by the 
logrank test). 
Table 1.  Patient baseline characteristics 
 
Characteristic* 
All 
 
(n=988) 
Low physical activity 
level 
(n=367) 
Moderate physical 
activity level 
(n=310) 
High physical 
activity level 
(n=311) 
 n (%) or median (range) 
Age, years 75 (65-97) 78 (65-96) 76 (65-97) 71 (65-90) 
Female gender 461 (47) 207 (56) 152 (49) 102 (33) 
Overt pulmonary embolism 684 (69) 254 (69) 215 (69) 215 (69) 
Unprovoked VTE† 598 (60.5) 195 (53.1) 196 (63.2) 207 (66.6) 
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History of major bleeding 101 (10) 51 (14) 25 (8) 25 (8) 
Recent surgery 148 (15) 45 (12) 52 (17) 51 (16) 
Cerebrovascular disease 92 (9) 45 (12) 33 (11) 14 (5) 
Cardiac disease‡ 241 (24) 117 (32) 62 (20) 62 (20) 
Diabetes mellitus 154 (16) 79 (22) 49 (16) 26 (8) 
Arterial hypertension 636 (64) 272 (74) 200 (65) 164 (53) 
Active cancer§ 177 (18) 82 (22) 58 (19) 37 (12) 
Chronic liver disease 14 (1) 7 (2) 4 (1) 3 (1) 
Chronic renal disease 185 (19) 83 (23) 60 (19) 42 (14) 
High risk of falls|| 457 (46) 248 (68) 135 (44) 74 (24) 
Anemia# 386 (39) 175 (48) 124 (40) 87 (28) 
Thrombocytopenia** 140 (14) 61 (17) 45 (15) 34 (11) 
Polypharmacy†† 503 (51) 249 (68) 154 (50) 100 (32) 
Platelet inhibitors‡‡ 320 (32) 149 (41) 99 (32) 72 (23) 
 
Characteristic  
All 
 
(n=988) 
Low physical 
activity level 
(n=367) 
Moderate physical 
activity level 
(n=310) 
High physical 
activity level 
(n=311) 
 n (%) or median (range) 
Pre-existing VKA 58 (6) 27 (7) 18 (6) 13 (4) 
Parenteral anticoagulation     
Low-molecular-weight heparin 467 (47) 158 (43) 147 (47) 162 (52) 
Unfractionated heparin 329 (33) 137 (37) 98 (32) 94 (30) 
Fondaparinux 158 (16) 58 (16) 50 (16) 50 (16) 
No parenteral anticoagulation 34 (3) 14 (4) 15 (5) 5 (2) 
 
Abbreviations: VTE= venous thromboembolism; VKA = vitamin K antagonist. 
*Data were missing for history of major bleeding (0.1%), hemoglobin (6%), and platelets (6%). 
†Any VTE unrelated to cancer or major surgery, immobilization, or estrogen therapy during the last 3 
months 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
‡Acute heart failure during the last three months, a known history of systolic or diastolic heart failure, left 
or right heart failure, forward or backward heart failure, left ventricular ejection fraction <40%, a 
myocardial infarction with or without ST elevation during the last three months, or history of coronary 
heart disease. 
§Solid or hematologic cancer requiring chemotherapy, radiotherapy, surgery, and/or palliative care during 
the last three months. 
||Patients who answered “yes” to at least one of the following validated questions were considered at 
high risk of falls: 1) Did you fall during the last year? If not, then, 2) Did you notice any problems with 
gait, balance, or mobility (50)? 
#Serum hemoglobin <130 g/l for men or <120 g/l for women. 
**Platelet count <150 G/l. 
††Pharmacotherapy with >4 different drugs. 
‡‡Use of aspirin, clopidogrel, prasugrel, or aspirin/dipyridamol. 
 
Table 2.  Incidence rates of a first bleeding by physical activity level 
Bleeding type Low physical  activity level 
Moderate physical 
activity level 
High physical  
activity level 
  
Major bleeding 
Incidence rate* 
Number of events 
Person-time, years 
 
 
11.6 (9.1 - 14.8) 
65 
561 
 
 
6.3 (4.5 - 8.8) 
34 
541 
 
 
3.1 (2.0 - 4.8) 
19 
619 
 
Clinically relevant non-major 
bleeding 
Incidence rate* 
Number of events 
Person-time, years 
 
 
14.0 (11.2 - 17.6) 
76 
542 
 
 
10.3 (7.9 - 13.5) 
53 
515 
 
 
7.7 (5.7 - 10.3) 
45 
586 
 
Fall-related bleeding 
Incidence rate* 
Number of events 
Person-time, years 
 
 
6.1 (4.4 - 8.5) 
36 
589 
 
 
1.9 (1.1 - 3.5) 
11 
565 
 
 
2.1 (1.2 - 3.5) 
13 
631 
 
 
*Events per 100 patient-years (95% confidence interval) 
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Table 3.  Percentage of time in a given INR range by physical activity level 
INR range* 
All 
 
(n=784) 
Low physical 
activity level 
(n=264) 
Moderate physical 
activity level 
(n=257) 
High physical 
activity level 
(n=263) 
P-
value 
<2.0 25% 29% 26% 21% <0.001 
2.0-3.0 58% 55% 57% 63% <0.001 
>3.0 16% 17% 17% 15% 0.49 
 
 
Abbreviation: INR = international normalized ratio. 
*Only patients who received oral anticoagulation within 14 days from 
diagnosis were included in this analysis (N=830). INR values 
obtained during the first seven days of each treatment period were 
omitted. A total of 46 patients with incalculable time in a given INR 
range (no or only one INR measurement available) were excluded. 
 
 
 
Table 4.  Association between physical activity level and bleeding 
Clinical characteristic Adjusted SHR* (95% CI) 
Major bleeding  
Physical activity level  
 Low 1 (reference) 
 Moderate 0.72 (0.45 - 1.13) 
 High 0.40 (0.22 - 0.72) 
Clinically relevant non-major bleeding  
Physical activity level  
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Abbreviation: SHR= sub-hazard ratio; CI= confidence interval. 
*Multivariate competing risk regression model, accounting for death as a competing risk. The SHR is adjusted 
for age, gender, overt pulmonary embolism, history of major bleedings, recent surgery, cerebrovascular 
disease, cardiac disease, diabetes mellitus, hypertension, active cancer, chronic liver disease, chronic renal 
disease, high risk of falls (self-reported fall during the last year or existing problems with gait, balance, or 
mobility), anemia (hemoglobin <130 g/l for men or <120 g/l for women), thrombocytopenia (<150 G/l), 
polypharmacy, platelet inhibitor therapy, and periods of vitamin K antagonist treatment as time-varying 
covariate. 
 
 
 
 
 
 
 
 
 
 
 Low 1 (reference) 
 Moderate 1.05 (0.73 - 1.51) 
 High 1.08 (0.69 - 1.67) 
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Figure 1.  Patient flow chart  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patients enrolled in SWITCO65+ 
(n = 1003)
Patients who withdrew 
consent early (within one day) 
or withdrew consent and did 
not allow the use of their data 
(n = 12)
Patients analyzed 
(n = 988) 
Patients with missing data on 
physical activity 
(n = 3) 
Screened patients aged ≥65 years with 
symptomatic pulmonary embolism or 
deep vein thrombosis 
(n= 1863)
Patients not eligible (n = 462) 
- Thrombosis at a different site than lower limb (n = 21) 
- Catheter-related thrombosis (n = 7) 
- Insufficient spoken ability in German or French (n = 51) 
- Inability to provide informed consent (n = 285) 
- Follow-up not possible (n = 192) 
Patients who did not consent 
(n = 398) 
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